Affimed

Lady in sunshine

Press Room | Events

Meet representatives of Affimed Therapeutics AG on following conferences:

 
Target Cancer Therapies, London, UK 26. - 27.05.2010
"Increased anti-tumor activity using targeted antibody therapeutics " speaker: Prof. Dr. Melvyn Little, CSO, deputy CEO of Affimed
Recombinant Antibodies 2010, Berlin Germany,   14. -18.06.2010
"Bispecific TandAbs for recruitment of T and NK cells", speaker: Prof. Dr. Melvyn Little, CSA, deputy CEO of Affimed
Next Generation Antibodies for Cancer Drugs, Geneve, Switzerland, 09.06.2009
Speaker: Prof. Dr. Melvyn Little, CSO, deputy CEO of Affimed
Bio Equity, München, Germany,   09. -10.06.2009
Dr. Rolf Günther, CEO of Affimed
Bio Capital Europe 2009, Amsterdam Netherlands, 21.04.2009
"Company presentation"; speaker: Dr. Rolf Günther, CEO of Affimed
Bio Europe 2008, Mannheim Germany 17. - 19.11.2008
"Company presentation"; speaker: Dr. Volker Lang, CBO of Affimed
Proteins Congress 2008, Berlin, Germany 20. - 21.11.2008
"Engineering Second Generation Antibody Formats for Clinical Applications" speaker: Prof. Dr. Melvyn Little, CSO, deputy CEO of Affimed
The 25th International Conference "Advances in the Application of the Monoclonal Antibodies in Clinical Oncology and Symposium on Cancer stem Cells"
Island of Rhodes, Greece, 16 - 18.06.2008

"Alternative antibody formats: fusions and fragments"; speaker: Prof. Dr. Melvyn Little, CSO, deputy CEO of Affimed
"Development of a bispecific tetravalent antibody for killing of EpCAM positive cells"; speaker: Dr. Fabrice le Gall, Head of Engineering, Affimed
Bio International Convention 2008, San Diego, USA 17. - 20.06.2008
Gavin D. Clark, Vice President Business Development, Dr. Volker Lang, CBO of Affimed, Dr. Stephan Knackmuss, Head of Sreening, Affimed, Partnering Forum
BioEquity, Amsterdam, Netherlands, 28. - 29.05.2008
Dr Florian Fischer, CFO of Affimed
2. Ernst & Young Life Science Day, Neue Börse Frankfurt/ Main, Germany, 08.05.2008
Dr. Rolf Günther, CEO of Affimed
BFF Biotech & Finance Forum, Stuttgart, Germany, 28.04.2008
Presentation of Dr. Florian Fischer, CFO of Affimed
AACR (American Association for Cancer Research)Annual Meeting 2008, San Diego, USA
12. -16.04.2008

Poster Session, 15. 04.2008 at 1 p.m >Development of a bispecific tetravalent antibody for treating Hodgkin's Disease<; Prof. Dr. Melvyn Little, CSO, deputy CEO, Affimed, Dr. Uwe Reusch, Head of Cell Culture, Affimed
Bio Europe Spring, Madrid, Spain, 07. - 09.04.2008
Bio Capital Europe 2008, Amsterdam, Netherlands, 05.03.2008
speaker: Dr Rolf Günther, CEO of Affimed
24th International Conference: "Advances in the Application of Monoclonal Antibodies in Clinical Oncology", Cyprus 16. 06.-20.06.2007
>Recruitment of NK cells for lysing tumor cells<; speaker: Prof. Dr. Melvyn Little, CSO, deputy CEO, Affimed
University of Vienna, Austria, 01.06.2007
>The recruitment of immune effector cells to lyse tumor cells using recombinant antibodies<; speaker: Prof. Dr. Melvyn Little, CSO, deputy CEO, Affimed
BIO 2007 International Convention, Boston, MA, USA, 06.-09.05.2007
www.bio2007.org
BioCapital Europe 2007, Amsterdam, Netherlands, 28.03.2007
speaker: Dr Rolf Günther, CEO of Affimed
www.biocapitaleurope.com
Antibodies in Discovery and Development, London, 28.-29.03.2007
»Increasing efficiency and productivity of technology, research and development of therapeutic antibody candidates«; speaker: Prof. Dr. Melvyn Little, CSO, deputy CEO, Affimed
World Biopharm Forum 2007, Development of new therapies for cancer, New Hall, Cambridge, UK, 19.-21.03.2007
»Exploiting the potential of NK cells to kill tumor cells«; speaker: Prof. Dr. Melvyn Little, CSO, deputy CEO, Affimed
New Binding Proteins Conference, Halle, 01.-03.03.2007
»Recruitment of immune cells to destroy tumor cells using novel antibody products«; speaker: Prof. Dr. Melvyn Little, CSO, deputy CEO, Affimed
Symposium Universitäts-Kinder- und Jugendklinik, Rostock, 23.-24.02.2007
»Rekombinante multivalente Antikörper für den Einsatz in der Onkologie«; speaker: Prof. Dr. Melvyn Little, CSO, deputy CEO, Affimed